Introduction
============

Bladder cancer, the most common malignancy of the urinary tract, poses a threat to an increasing number of humans ([@b1-ol-0-0-4556]). Progression of bladder tumors greatly increases the risk of metastasis and subsequent mortality. Consequently, early detection is crucial for improving patient prognosis and long-term survival.

Currently, cystoscopy is considered the gold standard for the detection of primary tumors and also the follow-up of patients after transurethral resection of bladder tumors, despite being an invasive approach ([@b2-ol-0-0-4556]). Urine cytology, another widely used detection method, has been firmly established as a useful adjunct, not only in the diagnosis, but also the follow-up of patients with bladder cancer ([@b3-ol-0-0-4556]). However, it is highly grade-dependent, and in low-grade cancers, it seems to not be sensitive enough. In addition, urine cytology also suffers from a high inter- and intra-observer variability, which limits its validity in screening for bladder tumors ([@b4-ol-0-0-4556],[@b5-ol-0-0-4556]).

With the aim of improving the lower sensitivity of cytology and increasing the detection of low-grade tumors, the uCyt+/ImmunoCyt test was developed by Fradet and Lockhard, it uses three monoclonal antibodies to detect urothelial cells in voided urine ([@b6-ol-0-0-4556]). A number of previous studies demonstrated its high sensitivity, and some investigators suggested that it also plays an important role in predicting urothelial tumor recurrence ([@b7-ol-0-0-4556]--[@b11-ol-0-0-4556]). The uCyt+/ImmunoCyt test has been in limited clinical and research use for a decade, but its diagnostic accuracy has never been subjected to a quantitative review. We therefore performed a systematic review and meta-analysis of uCyt+/ImmunoCyt test to fully assess its diagnostic accuracy in detecting bladder cancers and to guide future implementation.

Materials and methods
=====================

### Search methodology

We searched Medline and PubMed for articles that reported on the diagnostic sensitivity and specificity of the uCyt+/ImmunoCyt test for bladder cancers. The keywords used for the search were: (uCyt+/ImmunoCyt OR ImmunoCyt), (bladder cancer or urothelial tumor), sensitivity, specificity, and cytology. Only data from original published papers were collected, with meeting or conference abstracts being excluded. Primary sources from tracking references were also obtained from manual searches in review papers and original articles. Electronic databases were retrieved by two independent investigators. If the assessments of the investigators were not consistent, a discussion ensued whether to include the data or not. The articles included contained studies of the patients with bladder cancer diagnosed using the uCyt+/ImmunoCyt and cytology tests. The effect sizes of the studies seen as odds ratio (OR), sample size, gender, or range of age did not exclude any articles. Studies that only described the uCyt+/ImmunoCyt test or cytology data were excluded.

### Data extraction

Test performance data were extracted as a 2×2 table of true-positive (TP), false-positive (FP), false-negative (FN) and true-negative (TN) values directly from tabulated results ([Table I](#tI-ol-0-0-4556){ref-type="table"}). If these were not directly available, they were calculated from reported sensitivity, specificity, positive predictive value (PPV) and/or negative PV (NPV).

### Data analysis

The estimates of sensitivity, specificity, likelihood ratios (LRs), diagnostic odds ratio (DOR), and their 95% confidence intervals (95% CIs) were pooled for each study. The within- and between-study variation or heterogeneity were assessed by testing Cochrans Q-statistic. Heterogeneity was calculated using the formula I~2~ = 100% × (Q - df)/Q ([@b12-ol-0-0-4556]). A significant Q-statistic (P\<0.10) or I~2~-statistic (I~2~\>50) indicated heterogeneity across studies, and then the random effect model (REM) was used; otherwise, the fixed effect model (FEM) was used. The pooled estimate of ORs was obtained using the Mantel and Haenszel method for FEM, the DerSimonian and Laird and DerSimonian and Kacker method for REM ([@b13-ol-0-0-4556]--[@b15-ol-0-0-4556]).

The summary receiver operator characteristic (sROC) curve was used to graphically determine performance following testing for correlation between sensitivity and specificity \[as the logit TP rate (TPR) vs. the logit FP rate (FPR)\] ([@b16-ol-0-0-4556]).

The area under the curve (AUC) and an index Q were discussed as potentially useful summaries of the curve. An upper bound was derived for the AUC based on an exact analytic expression for the homogeneous situation, and a lower bound based on the limit case Q, defined by the point where sensitivity equals specificity: Q is invariant to heterogeneity ([@b17-ol-0-0-4556]).

Analyses were performed using the freeware Meta-Disc version 1.4 (Universidad Complutense, Madrid, Spain) and STATA package version 13.0 (Stata Corporation, College Station, TX, USA). All P-values were two-sided. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

In total, 45 potentially relevant studies were identified ([Fig. 1](#f1-ol-0-0-4556){ref-type="fig"}). During the abstract screening, 15 articles were excluded. Thirty studies were considered for full publication review. Of these, 23 were excluded (nine because there were no data available, eight because they were reviews, one because it was a non-English article, five because they only included cytology or ImmunoCyt data and no comparison). Seven studies were eventually analyzed ([Table I](#tI-ol-0-0-4556){ref-type="table"}) ([@b7-ol-0-0-4556],[@b11-ol-0-0-4556],[@b18-ol-0-0-4556]--[@b22-ol-0-0-4556]). These studies were published between 2004 and 2014, and included a total of 1,602 patients with bladder cancer. Their sample size ranged from 90 to 870. In these seven studies, a combination of cystoscopy and biopsy was used as the gold standard of bladder cancer.

### Assessment of study quality

Studies meeting the criteria were quality assessed using positive scoring in a modified 23-point Standards for the Reporting of Diagnostic Accuracy Studies (STARD) proforma ([@b23-ol-0-0-4556],[@b24-ol-0-0-4556]). Two readers (F.T. and M.M.) independently assessed the included studies according to the prearranged proforma. An open discussion was subsequently held in order to resolve any disagreement between the readers. STARD scores for each study are provided in [Table I](#tI-ol-0-0-4556){ref-type="table"}.

### Pooled sensitivity, specificity, LR+, LR-, and DOR

We summarized the overall meta-analysis of bladder cancer patients with the ImmunoCyt test, cytology test, and combined method (Combination of ImmunoCyt and Cytology) ([Table II](#tII-ol-0-0-4556){ref-type="table"}). The REM or FEM was used to combine the data of TP, FP, FN, and TN numbers.

### ImmunoCyt test

The pooled sensitivity of the ImmunoCyt test for all seven studies included in the final meta-analysis was 72.5% (95% CI, 68.3--76.5%), the pooled specificity 65.7% (95% CI, 62.9--68.5%), the pooled positive LR was 2.578 (95% CI, 2.003--3.318), the pooled negative LR was 0.385 (95% CI, 0.327--0.452), and the pooled DOR was 7.114 (95% CI, 4.709--10.748) ([Table II](#tII-ol-0-0-4556){ref-type="table"}).

### Cytology test

The pooled sensitivity of cytology test was 56.6% (95% CI, 52.1--61.1%), the pooled specificity was 90.6% (95% CI, 88.7--92.3%), the pooled positive LR was 3.862 (95% CI, 2.347--6.353), the pooled negative LR was 0.459 (95% CI, 0.320--0.658), and the pooled DOR was 10.269 (95% CI, 7.501--15.795) ([Table II](#tII-ol-0-0-4556){ref-type="table"}).

### Combined method (ImmunoCyt and cytology)

We also collected the pooled meta-analysis of bladder cancer patients with the combined method. The pooled sensitivity was 83.3% (95% CI, 79.6--86.5%), the pooled specificity was 64.4% (95% CI, 61.5--67.2%), the pooled positive LR was 2.804 (95% CI, 2.163--3.636), the pooled negative LR was 0.228 (95% CI, 0.149--0.350), and the pooled DOR was 13.50 (95% CI, 7.847--23.238) ([Table II](#tII-ol-0-0-4556){ref-type="table"}).

### AUC and Q index in the three tests

The AUC and Q index of ImmunoCyt test were 0.7910 and 0.7280, those of the cytology test 0.8239 and 0.7570, and those of the combined method 0.8554 and 0.7863, respectively ([Figs. 2](#f2-ol-0-0-4556){ref-type="fig"}--[4](#f4-ol-0-0-4556){ref-type="fig"}).

### Publication bias

Eggers test was used to assess the publication bias. For all samples, Eggers test provided no evidence of publication bias for this meta-analysis. Detailed information is provided in [Fig. 5](#f5-ol-0-0-4556){ref-type="fig"}.

Discussion
==========

As a useful adjunct for cystoscopy, cytology has been used for more than 60 years for the diagnosis of urothelial carcinoma (UC). The test suffers from low sensitivity (38--51%), but boasts a high specificity (94--98%), particularly for high-grade disease ([@b25-ol-0-0-4556]). The reliability of cytology results depends on sample quality and cytopathologist experience to some extent. Atypical results are often found in urine cytology tests ([@b6-ol-0-0-4556]). Among these atypical cytology results, biopsy reveals that malignancy underlies 23--68% of them. Investigators have also found that its sensitivity is highly associated with tumor stage. For patients with higher-grade bladder cancer, it appears to be more sensitive ([@b26-ol-0-0-4556]--[@b29-ol-0-0-4556]).

With the aim of improving the low sensitivity of cytology and the detection of low-risk UC, many voided urine biomarker assays such as UroVysion, NMP22, BTA TRAK, and ImmunoCyt/uCyt+ have been developed but have yet to gain widespread clinical application. The ImmunoCyt test performance has been well studied since its introduction by Fradet and Lockhard in 1997 ([@b6-ol-0-0-4556],[@b30-ol-0-0-4556]). It is a triple immunofluorescent monoclonal antibody assay associated with UC, approved by the US Food and Drug Administration. A previous series reported a sensitivity of 74--87% and specificity of 62--78%, with PPVs and NPVs of 26--67% and 91--96%, respectively ([@b6-ol-0-0-4556]).

Additionally, the ImmunoCyt test can also provide important information in evaluating hematuria, particularly in patients with negative imaging and cystoscopy but atypical cytology ([@b31-ol-0-0-4556]).

Many studies have reported on the diagnostic accuracy of the ImmunoCyt and cytology tests in detecting bladder cancer ([@b29-ol-0-0-4556]--[@b32-ol-0-0-4556]). The results of those studies, however, have been met with skepticism due to their small sample sizes or low statistical power. In the present meta-analysis, we combined seven separate studies, consisting of 1,602 patients to compare the diagnostic accuracy of the ImmunoCyt test with the urine cytology test in detecting bladder cancer. We found that the ImmunoCyt test had a higher sensitivity than the urine cytology test, but the specificity, positive LR, negative LR, and DOR of the ImmunoCyt test were lower compared with the urine cytology test. In addition, the AUC and Q index of cytology were superior to those of the ImmunoCyt test. Based on these comparisons, we can conclude that the ImmunoCyt test would not replace the urine cytology test in detecting bladder cancer.

We also collected data of a combined method (combination of ImmunoCyt test and cytology). The pooled sensitivity, specificity, positive LR, negative LR, DOR, AUC, and Q index were 0.833, 0.644, 2.804, 0.228, 13.50, 0.8554 and 0.7863, respectively. These data suggest that the ability of cytology to detect malignancies of the bladder can be highly improved in combination with ImmunoCyt. The results of the present study are in agreement with previous findings of Mian *et al* regarding the clinical usefulness of combining the two tests ([@b32-ol-0-0-4556]). Using the uCyt1/ImmunoCyt test in combination with cytology to detect bladder cancer appeared to improve the overall sensitivity for cytology alone. Furthermore, the use of the two tests in combination constitute a potential alternative option to limit the amount of cystoscopic evaluations required for the follow-up of patients with low-risk bladder cancer.

One limitation of our study is heterogeneity. The considerable amount of heterogeneity detected between the studies suggests a need for caution when pooling the diagnostic accuracy measures together. Additionally, between-study heterogeneities may distort the meta-analysis. The degree of heterogeneity is one of the major concerns in a meta-analysis, as non-homogeneous data are liable to result in misleading results ([@b33-ol-0-0-4556]). Different populations also contribute to the heterogeneity. Therefore, the results of this meta-analysis should be interpreted with caution. We minimized the likelihood of bias by developing a detailed protocol prior to initiating the study, by performing a rigorous search of published studies and by using explicit methods for study selection, data extraction, and data analysis.

Another limitation common to diagnostic meta-analyses is the lack of clarity, quality, and standardization in the methodology of diagnostic studies. Studies were assessed for quality using STARD proforma to quantify the methodology of the study design. Consequently, we excluded certain studies due to ambiguity between the raw data and the diagnostic accuracy data in the process of data extraction.

In conclusion, in this meta-analysis, we have evaluated the pooled sensitivity, specificity, positive LR, negative LR, DOR, AUC, and Q index of three tests (ImmunoCyt, cytology, and combined test) from seven studies. We found that ImmunoCyt was superior to cytology only in sensitivity, however, inferior to cytology in specificity, positive LR, negative LR, DOR, AUC, and Q index. In conclusion, cytology remains integral in the detection of bladder cancer. Meta-analysis of the combined tests suggests that the use of ImmunoCyt and cytology in combination significantly improves the sensitivity for detecting bladder cancer and promises to be an alternative option in the clinical setting.
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###### 

Characteristics of studies included in the meta-analysis (n=7).

                                                                uCyt+/ ImmunoCyt   Cytology   Combination of both                                                                
  ---------------------------------------- ------ ------ ------ ------------------ ---------- --------------------- ------ ------- ------- ------- ------ ------ ------- ------- ------
  Yafi *et al* ([@b18-ol-0-0-4556])        2014   109      18     52                   5        31                    21     36        4     47      22     54       6     29      20
  Soyuer *et al* ([@b19-ol-0-0-4556])      2009     90     15     45                   5          9                   31     41      12      13      24     48       5       6     31
  Horstmann *et al* ([@b20-ol-0-0-4556])   2009   221      16     82                 30         31                    78     95      41      18      67   105      47        8     61
  Têtu *et al* ([@b7-ol-0-0-4556])         2005   870      19   100                281          36                  453      39      17      97    717    114    284       22    450
  Toma *et al* ([@b21-ol-0-0-4556])        2004   120      15     33                 20           9                   58     36      16        6     62     37     21        5     57
  Hautmann *et al* ([@b22-ol-0-0-4556])    2004     94     14     19                 16         11                    48     22      13        8     51     25       9       5     55
  Sullivan *et al* ([@b11-ol-0-0-4556])    2009     98     18     20                 26           6                   46       5       2     21      70     20     26        6     46

TP, true positive; FP, false positive; FN, false negative; TN, true negative; STARD, Standards for the Reporting of Diagnostic Accuracy Studies.

###### 

The indices of bladder cancer diagnosed by ImmunoCyt test and cytology test.

                                      Test of association   Test of heterogeneity            Egger\'s test for publication bias                        
  --------------------- ------------- --------------------- ----------------------- -------- ------------------------------------ ------ ----- ------- -------
  uCyt+/ImmunoCyt       Sensitivity   0.725                 0.683--0.765            9.66     0.140                                37.9   FEM   2.56    0.051
                        Specificity   0.657                 0.629--0.685            23.23    0.001                                74.2   REM           
                        Positive LR   2.578                 2.003--3.318            17.56    0.007                                65.8   REM           
                        Negative LR   0.385                 0.327--0.452            8.43     0.208                                28.9   FEM           
                        DOR           7.114                 4.709--10.748           11.24    0.081                                46.6   REM           
  Cytology              Sensitivity   0.566                 0.521--0.611            132.48   0.000                                95.5   REM   −0.72   0.505
                        Specificity   0.906                 0.887--0.923            161.32   0.000                                96.3   REM           
                        Positive LR   3.862                 2.347--6.353            36.95    0.000                                83.8   REM           
                        Negative LR   0.459                 0.320--0.658            66.46    0.000                                91.0   REM           
                        DOR           10.269                7.501--15.795           8.77     0.187                                31.6   FEM           
  Combination of both   Sensitivity   0.833                 0.796--0.865            28.17    0.000                                78.7   REM   1.80    0.132
                        Specificity   0.644                 0.615--0.672            34.10    0.000                                82.4   REM           
                        Positive LR   2.804                 2.163--3.636            23.59    0.001                                74.6   REM           
                        Negative LR   0.228                 0.149--0.350            21.42    0.002                                72.0   REM           
                        DOR           13.50                 7.847--23.238           14.56    0.024                                58.8   REM           

CI, confidence interval; LR, likelihood ratio; DOR, diagnostic odds ratio; FEM, fixed effect model; REM, random effect model.
